Modification of extracorporeal photopherisis technology with porphyrin precursors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10695371
APP PUB NO 20170042938A1
SERIAL NO

15306442

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to the use of a photoactivatable Porphyrin-Derivative in extracorporeal photophoresis (ECP) treatment, in which a patient's blood or part of it containing sad Porphyrin-derivative is/are exposed to light of a wavelength which activates said photoactivatable Porphyrin-Derivative.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
OSLO UNIVERSITETSSYKEHUS HFP O BOX 4950 NYDALEN N-0424 OSLO N-0424

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Christensen, Eidi Trondheim, NO 1 0
Gederaas, Odrun Arna Trondheim, NO 1 0
Holien, Toril Trondheim, NO 1 0
Nesland, Jahn M Asker, NO 2 4
Peng, Qian Oslo, NO 30 241
Warloe, Trond Oslo, NO 14 125

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Dec 30, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 30, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00